RMGNF yields 5.01% · PFE yields 6.20%● Live data
📍 RMGNF pulled ahead of the other in Year 1
Combined, RMGNF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RMGNF + PFE for your $10,000?
RHI Magnesita N.V., together with its subsidiaries, develops, produces, sells, installs, and maintains refractory products and systems used in industrial high-temperature processes worldwide. It offers magnesia spinel, dolomite, dolomite-magnesia, magnesia-chrome, alumina, alumina silicate, and mortars for the cement industry; shaped products based on silicon carbide, magnesia, zirconium, fireclay, and alumina; unshaped refractories; and high-temperature insulation, and ceramic and metallic anchoring systems. The company also provides induction and electric arc furnaces, AOD converters, dome and delta, ladles, isostatically pressed products, and slide gates. In addition, the company offers zircon-magnesia, mullite /andalusite, chrome-alumina, zircon, silica, and calcium aluminate materials. Further, the company provides high-purity magnesia and magnesia-chromite bricks, magnesia-carbon bricks, concrete with anti-wetting system, ceramic and metal anchors, sense and insulating concretes, ramming mixes, and low cement castables, as well as precast shapes, alumina-silica, insulating monolithic parts; and monolithic products. Additionally, it provides raw, caustic, and sintered magnesia, dolomite and sintered dolomite, slag conditioners, magnesium oxide, spinels, agalmatolite, chromite, grogs, and commodities. The company also offers electromechanical maintenance, repairs, assemblies, refractory maintenance and application; solutions development and monitoring; engineering, projects, lining, and metal working factory services. In addition, it provides iron, steel, continuous casting, and non-ferrous solutions. RHI Magnesita N.V. offers solutions for various ladles, tundish, hydraulical or electrical power, steel plant aggregates, and robotic handling sectors. The company was founded in 1834 and is headquartered in Vienna, Austria.
Full RMGNF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.